Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3181/00379727-66-16092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASGCL: Adaptive Sparse Mapping-based graph contrastive learning network for cancer drug response prediction.
PLoS Comput Biol
January 2025
School of Software, Taiyuan University of Technology, Taiyuan, China.
Personalized cancer drug treatment is emerging as a frontier issue in modern medical research. Considering the genomic differences among cancer patients, determining the most effective drug treatment plan is a complex and crucial task. In response to these challenges, this study introduces the Adaptive Sparse Graph Contrastive Learning Network (ASGCL), an innovative approach to unraveling latent interactions in the complex context of cancer cell lines and drugs.
View Article and Find Full Text PDFTailoring anaesthetic strategies for diabetes research: Acepromazine vs. medetomidine in Aachen minipigs.
PLoS One
January 2025
Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Pre-established anaesthetic protocols in animal models might unexpectedly interfere with the main outcome of scientific projects and therefore they need to account for the specific research goals. We aimed to optimize the anaesthetic protocol and animal handling strategies in a diabetes-related-study exemplifying how the anaesthetic approach must be adjusted for individual research targets. Aachen minipigs were used as a model to test long-lasting skin glucose sensors for diabetic human patients.
View Article and Find Full Text PDFLow skeletal muscle mass contributes to the prognosis of patients with superficial esophageal cancer treated with definitive chemoradiotherapy.
Esophagus
January 2025
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Herein, we aimed to examine the relationship between sarcopenia, neutrophil-lymphocyte ratio (NLR), Charlson comorbidity index (CCI), and prognostic nutritional index (PNI) in patients with superficial esophageal carcinoma who underwent definitive chemoradiotherapy (CRT).
Methods: We retrospectively analyzed 100 patients (87 males) diagnosed with cT1N0M0 esophageal squamous cell carcinoma. The included patients underwent CRT as an initial treatment.
Partially hydrolyzed guar gum alleviates neurological deficits and gastrointestinal dysfunction in mice with traumatic brain injury.
Neurosurg Rev
January 2025
Department of Critical Care Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Zhou shan hui shui Community,199 Hailing South Road, Taizhou, Jiangsu Province, 225300, China.
Traumatic brain injury (TBI)-associated neuroinflammation and neurotoxicity can induce gastrointestinal dysfunction through the brain-gut axis. Partially hydrolyzed guar gum (PHGG) was demonstrated to exert beneficial health effects by altering gut microbiota and short-chain fatty acids (SCFAs) production. Our study aimed to explore the effects of PHGG on gastrointestinal dysfunction in TBI mouse models.
View Article and Find Full Text PDFAnti-GPC3 antibody and cell-penetrating peptide CPP44 dual-ligand modified liposomes for targeted delivery of arsenic trioxide in the treatment of hepatocellular carcinoma.
J Drug Target
January 2025
College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Arsenic trioxide (ATO), the active ingredient in Chinese arsenic, effectively inhibits hepatocellular carcinoma (HCC) cell growth, but its clinical application is limited by the lack of a targeted delivery system. Phosphatidylinositol proteoglycan 3 (GPC3) is specifically expressed in HCC, and CPP44 is a cell-penetrating peptide that targets HCC cells. Here, we developed a liposome incorporating ATO with dual surface modifications of anti-GPC3 antibody and CPP44.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!